AR066872A1 - Compuesto de quinolona y composicion farmaceutica - Google Patents
Compuesto de quinolona y composicion farmaceuticaInfo
- Publication number
- AR066872A1 AR066872A1 ARP080102390A ARP080102390A AR066872A1 AR 066872 A1 AR066872 A1 AR 066872A1 AR P080102390 A ARP080102390 A AR P080102390A AR P080102390 A ARP080102390 A AR P080102390A AR 066872 A1 AR066872 A1 AR 066872A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- groups
- lower alkyl
- alkyl
- alkoxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/24—Oxygen atoms attached in position 8
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/40—Nitrogen atoms attached in position 8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
Abstract
El compuesto de quinolona tiene un efecto de mejora funcional, que suprime el avance de la disfuncion neurologica inhibiendo el avance cronico de la enfermedad de Parkinson o protegiendo a las neuronas de dopamina de la etiología de la enfermedad, prolongando de este modo el período antes de que comience la primera administracion. Procesos de obtencion de las mismas y composiciones farmacéuticas. Reivindicacion 1: Un compuesto de quinolona representado por la Formula general (1): o una sal del mismo, caracterizado porque: R1 representa un átomo de hidrogeno, un grupo alquilo inferior, un grupo ciclo alquilo C3-8 alquilo inferior o un grupo alcoxi inferior alquilo inferior; R2 representa un átomo de hidrogeno, un grupo alquilo inferior o un grupo alquilo inferior substituido con halogeno; R3 representa un grupo fenilo, un grupo furilo, un grupo tienilo o un grupo piridilo, estando cada uno de los grupos opcionalmente substituido con uno o más grupos seleccionados entre el grupo que consiste en los siguientes (1) a (16) en el anillo aromático o heterocíclico representado por el R3 arriba mencionado: (1) grupos alquilo inferior, (2) grupos alcoxi inferior, (3) grupos alcoxi inferior substituidos con halogeno, (4) un grupo fenoxi, (5) grupos alquiltio inferior, (6) un grupo hidroxi, (7) grupos hidroxi alquilo inferior, (8) átomos de halogeno, (9) grupos alcanoilo inferior, (10) grupos alcoxicarbonilo inferior, (11) grupos amino opcionalmente substituidos con uno o más grupos alquilo inferior, (12) grupos carbamoilo opcionalmente substituidos con uno o más grupos alquilo inferior, (13) grupo alcoxi inferior ciclo alquilo C3-8, (14) grupos pirrolidinilo carbonilo, (15) grupos morfolinilo carbonilo, y (16) un grupo carboxilo; R4 representa un átomo de halogeno; R5 representa un átomo de hidrogeno o un átomo de halogeno; R6 representa un átomo de hidrogeno; y R7 representa uno cualquiera de los grupos (1) a (15) a continuacion: (1) un grupo hidroxi, (2) un átomo de halogeno, (3) un grupo alcoxi inferior, (4) un grupo alcoxi inferior substituido con halogeno, (5) un grupo hidroxi alcoxi inferior, (6) un grupo alcoxi inferior alcoxi inferior, (7) un grupo amino opcionalmente substituido con uno o más miembros seleccionados entre el grupo que consiste en grupos alquilo inferior, grupos alcoxi inferior alquilo inferior, y grupos ciclo alquilo C3-8, (8) un grupo amino alcoxi inferior opcionalmente substituido en el grupo amino con uno o más miembros seleccionados entre el grupo que consiste en grupos alquilo inferior, grupos alcanoilo inferior, grupos alquilo sulfonilo inferior y grupos carbamoilo opcionalmente substituidos con uno o más grupos alquilo inferior, (9) a grupo cicloalquiloxi C3-8, (10) un grupo cicloalquilo C3-8 alcoxi inferior, (11) un grupo tetrahidrofurilo alcoxi inferior, (12) un grupo alquiltio inferior, (13) un grupo heterocíclico seleccionado entre el grupo que consiste en grupos morfolinilo, grupos pirrolidinilo, grupos furilo, grupos tienilo y grupos benzotienilo, (14) un grupo fenilo alcoxi inferior alcoxi inferior, y (15) un grupo pirrolidinilo carbonilo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2007150819 | 2007-06-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR066872A1 true AR066872A1 (es) | 2009-09-16 |
Family
ID=39730840
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080102390A AR066872A1 (es) | 2007-06-06 | 2008-06-05 | Compuesto de quinolona y composicion farmaceutica |
Country Status (28)
| Country | Link |
|---|---|
| US (5) | US8269011B2 (es) |
| EP (1) | EP2152699B1 (es) |
| JP (1) | JP5063708B2 (es) |
| KR (4) | KR101472262B1 (es) |
| CN (1) | CN101679392B (es) |
| AR (1) | AR066872A1 (es) |
| AT (1) | ATE499368T1 (es) |
| AU (1) | AU2008260867B2 (es) |
| BR (1) | BRPI0812234A2 (es) |
| CA (1) | CA2688448C (es) |
| CO (1) | CO6270258A2 (es) |
| CY (1) | CY1111936T1 (es) |
| DE (1) | DE602008005137D1 (es) |
| DK (1) | DK2152699T3 (es) |
| ES (1) | ES2360572T3 (es) |
| HK (1) | HK1139153A1 (es) |
| HR (1) | HRP20110151T1 (es) |
| IL (1) | IL201894A (es) |
| MX (1) | MX2009013239A (es) |
| MY (1) | MY148098A (es) |
| NZ (1) | NZ580919A (es) |
| PL (1) | PL2152699T3 (es) |
| PT (1) | PT2152699E (es) |
| RU (1) | RU2490259C2 (es) |
| SI (1) | SI2152699T1 (es) |
| TW (1) | TWI366565B (es) |
| UA (1) | UA98789C2 (es) |
| WO (1) | WO2008150029A1 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI366565B (en) * | 2007-06-06 | 2012-06-21 | Otsuka Pharma Co Ltd | Quinolone compound and pharmaceutical composition |
| US8598354B2 (en) * | 2008-12-05 | 2013-12-03 | University Of South Florida | Compounds having antiparasitic or anti-infectious activity |
| EP2370411A4 (en) * | 2008-12-05 | 2012-10-24 | Univ Oregon Health & Science | COMPOUNDS HAVING ANTIPARASITIC OR ANTI-INFECTIOUS ACTIVITY |
| TWI472525B (zh) * | 2008-12-05 | 2015-02-11 | Otsuka Pharma Co Ltd | 喹啉酮化合物及藥學組成物 |
| US20110251180A1 (en) * | 2008-12-05 | 2011-10-13 | Otsuka Pharmaceutical Co., Ltd. | Pharmaceutical agent comprising quinolone compound |
| EP2509414B1 (en) * | 2009-12-09 | 2017-08-09 | Barlaa B.V. | Micro-colloidal silicic acid / boric acid composition and a method of preparing a bioenhancing solution and powder |
| JP5769504B2 (ja) * | 2010-06-04 | 2015-08-26 | 大塚製薬株式会社 | 医薬 |
| WO2012066330A1 (en) | 2010-11-17 | 2012-05-24 | Heptares Therapeutics Limited | Compounds useful as a2a receptor inhibitors |
| WO2017112678A1 (en) | 2015-12-21 | 2017-06-29 | Rima Mcleod | Compounds and methods for treating, detecting, and identifying compounds to treat apicomplexan parasitic diseases |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3416695A1 (de) | 1984-05-05 | 1985-11-07 | Bayer Ag, 5090 Leverkusen | Amidinohydrazone von tetralin-, chromon-, thiochromon- und tretrahydrochinolin-derivaten, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln |
| US5081121A (en) * | 1988-05-24 | 1992-01-14 | Tatsushi Osawa | 4(1h)-quinolone derivatives |
| GB9022785D0 (en) | 1990-10-19 | 1990-12-05 | Merck Sharp & Dohme | Therapeutic agents |
| GB9026389D0 (en) | 1990-12-05 | 1991-01-23 | Merck Sharp & Dohme | Therapeutic agents |
| MX9200299A (es) | 1991-02-07 | 1992-12-01 | Roussel Uclaf | Nuevos derivados biciclicos nitrogenados, su procedimiento de preparacion los nuevos compuestos intermedios obtenidos su aplicacion como medicamentos y las composiciones farmaceuticas que los contienen. |
| GB9125485D0 (en) | 1991-11-29 | 1992-01-29 | Merck Sharp & Dohme | Therapeutic agents |
| GB9125515D0 (en) | 1991-11-29 | 1992-01-29 | Merck Sharp & Dohme | Therapeutic agents |
| DE69309297T2 (de) | 1992-10-30 | 1997-07-03 | Pfizer | Neuroprotektive 3,4-dihydro-2(1h)-chinolone |
| FR2709489B1 (fr) | 1993-08-31 | 1995-10-20 | Adir | Nouveaux dérivés de 2-(1H)-quinoléinone, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent. |
| EP0800504B1 (en) | 1994-12-30 | 1999-12-01 | Ligand Pharmaceuticals Incorporated | Tricyclic retinoids, methods for their production and use |
| GB9621757D0 (en) | 1996-10-18 | 1996-12-11 | Ciba Geigy Ag | Phenyl-substituted bicyclic heterocyclyl derivatives and their use |
| WO1998048790A1 (en) | 1997-04-28 | 1998-11-05 | Anticancer, Inc. | Use of genistein and related compounds to treat certain sex hormone related conditions |
| IT1296985B1 (it) | 1997-12-19 | 1999-08-03 | Zambon Spa | Derivati benzazinici inibitori della fosfodiesterasi 4 |
| FR2784988B1 (fr) * | 1998-10-23 | 2002-09-20 | Adir | Nouveaux composes dihydro et tetrahydroquinoleiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| EP1147094A1 (en) | 1999-01-15 | 2001-10-24 | Novo Nordisk A/S | Non-peptide glp-1 agonists |
| US6518301B1 (en) | 1999-04-16 | 2003-02-11 | Astrazeneca Ab | Estrogen receptor-β ligands |
| US6413956B1 (en) | 1999-05-06 | 2002-07-02 | Neurogen Corporation | Substituted 4-oxo-quinoline-3-carboxamides |
| FR2797444B1 (fr) * | 1999-08-13 | 2003-02-07 | Lafon Labor | Compositions pharmaceutiques comprenant des 4-quinolones |
| AUPQ266199A0 (en) | 1999-09-06 | 1999-09-30 | Novogen Research Pty Ltd | Compositions and therapeutic methods involving isoflavones and analogues thereof |
| TWI243173B (en) | 1999-11-17 | 2005-11-11 | Akzo Nobel Nv | Spiro[2H-1-benzopyran-2,4'-piperidine] derivatives |
| FR2813791B1 (fr) | 2000-09-14 | 2004-03-12 | Lafon Labor | Utilisation de 2- et 4-quinolones pour inhiber la neo-proliferation intimale |
| GB0023918D0 (en) | 2000-09-29 | 2000-11-15 | King S College London | Antiparasitic compounds |
| EP1326593A1 (en) | 2000-10-13 | 2003-07-16 | AstraZeneca AB | ESTROGEN RECEPTOR-$g(b) LIGANDS |
| EP1368024A4 (en) | 2001-03-16 | 2009-03-18 | Novogen Res Pty Ltd | TREATMENT OF RESTENOSIS |
| AUPR846401A0 (en) | 2001-10-25 | 2001-11-15 | Novogen Research Pty Ltd | 6-Hydroxy isoflavones, derivatives and medicaments involving same |
| SE0103648D0 (sv) * | 2001-11-01 | 2001-11-01 | Astrazeneca Ab | Therapeutic quinolone compounds |
| AU2002950217A0 (en) | 2002-07-16 | 2002-09-12 | Prana Biotechnology Limited | 8- Hydroxy Quinoline Derivatives |
| US20040033480A1 (en) | 2002-08-15 | 2004-02-19 | Wong Norman C.W. | Use of resveratrol to regulate expression of apolipoprotein A1 |
| US20050080024A1 (en) | 2002-08-15 | 2005-04-14 | Joseph Tucker | Nitric oxide donating derivatives for the treatment of cardiovascular disorders |
| GB0222516D0 (en) | 2002-09-27 | 2002-11-06 | Karobio Ab | Novel compounds |
| US20070037848A1 (en) | 2003-04-03 | 2007-02-15 | Masters Colin L | Treatment of neurological conditions |
| EP1613322A4 (en) | 2003-04-11 | 2008-08-13 | Taigen Biotechnology Co Ltd | AMINOQUINOLINE COMPOUNDS |
| US20060025337A1 (en) | 2003-07-01 | 2006-02-02 | President And Fellows Of Harvard College | Sirtuin related therapeutics and diagnostics for neurodegenerative diseases |
| MXPA06003838A (es) | 2003-10-10 | 2006-07-03 | Resverlogix Corp | Tratamiento de enfermedades asociadas con el elemento mejorador de egr-1. |
| EP1686981A4 (en) | 2003-11-19 | 2011-02-23 | Novogen Res Pty Ltd | COMPOSITIONS AND METHODS FOR COMBINED RADIATION THERAPY AND CHEMOTHERAPY |
| KR100636423B1 (ko) * | 2004-04-30 | 2006-10-19 | 한국화학연구원 | 신규한 퀴놀리논 유도체, 이의 제조방법 및 이를유효성분으로 하는 약학적 조성물 |
| US7935714B2 (en) * | 2004-05-18 | 2011-05-03 | Bright Future Pharmaceutical Laboratories | Compositions for sleeping disorders |
| GB0420702D0 (en) * | 2004-09-17 | 2004-10-20 | Univ Birmingham | Use of methanofullerene derivatives as resist materials and method for forming a resist layer |
| US7846915B2 (en) | 2004-10-20 | 2010-12-07 | Resverlogix Corporation | Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases |
| EP1886996A1 (en) | 2006-08-10 | 2008-02-13 | Ferrer Internacional, S.A. | 1H-Quinolin-4-one compounds, with affinity for the GABA receptor, processes, uses and compositions |
| TWI366565B (en) | 2007-06-06 | 2012-06-21 | Otsuka Pharma Co Ltd | Quinolone compound and pharmaceutical composition |
| WO2009053799A1 (en) | 2007-10-24 | 2009-04-30 | Glenmark Pharmaceuticals, S.A. | Novel cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation |
| TWI472525B (zh) * | 2008-12-05 | 2015-02-11 | Otsuka Pharma Co Ltd | 喹啉酮化合物及藥學組成物 |
| US20110251180A1 (en) * | 2008-12-05 | 2011-10-13 | Otsuka Pharmaceutical Co., Ltd. | Pharmaceutical agent comprising quinolone compound |
-
2008
- 2008-05-26 TW TW097119343A patent/TWI366565B/zh not_active IP Right Cessation
- 2008-06-05 AR ARP080102390A patent/AR066872A1/es unknown
- 2008-06-06 WO PCT/JP2008/060804 patent/WO2008150029A1/en active Application Filing
- 2008-06-06 PT PT08765545T patent/PT2152699E/pt unknown
- 2008-06-06 KR KR1020147002638A patent/KR101472262B1/ko not_active IP Right Cessation
- 2008-06-06 CA CA2688448A patent/CA2688448C/en not_active Expired - Fee Related
- 2008-06-06 KR KR1020147019304A patent/KR101536883B1/ko not_active IP Right Cessation
- 2008-06-06 KR KR1020117030138A patent/KR101403817B1/ko not_active IP Right Cessation
- 2008-06-06 UA UAA200913768A patent/UA98789C2/ru unknown
- 2008-06-06 DK DK08765545.2T patent/DK2152699T3/da active
- 2008-06-06 AU AU2008260867A patent/AU2008260867B2/en not_active Ceased
- 2008-06-06 CN CN2008800183772A patent/CN101679392B/zh not_active Expired - Fee Related
- 2008-06-06 AT AT08765545T patent/ATE499368T1/de active
- 2008-06-06 NZ NZ580919A patent/NZ580919A/en unknown
- 2008-06-06 US US12/599,003 patent/US8269011B2/en not_active Expired - Fee Related
- 2008-06-06 DE DE602008005137T patent/DE602008005137D1/de active Active
- 2008-06-06 PL PL08765545T patent/PL2152699T3/pl unknown
- 2008-06-06 EP EP08765545A patent/EP2152699B1/en not_active Not-in-force
- 2008-06-06 KR KR1020107000161A patent/KR101154613B1/ko not_active IP Right Cessation
- 2008-06-06 JP JP2009550846A patent/JP5063708B2/ja not_active Expired - Fee Related
- 2008-06-06 SI SI200830217T patent/SI2152699T1/sl unknown
- 2008-06-06 MY MYPI20094786A patent/MY148098A/en unknown
- 2008-06-06 MX MX2009013239A patent/MX2009013239A/es active IP Right Grant
- 2008-06-06 ES ES08765545T patent/ES2360572T3/es active Active
- 2008-06-06 RU RU2009149612/04A patent/RU2490259C2/ru not_active IP Right Cessation
- 2008-06-06 BR BRPI0812234-2A2A patent/BRPI0812234A2/pt not_active IP Right Cessation
-
2009
- 2009-11-03 IL IL201894A patent/IL201894A/en not_active IP Right Cessation
-
2010
- 2010-01-04 CO CO10000239A patent/CO6270258A2/es not_active Application Discontinuation
- 2010-06-14 HK HK10105911.3A patent/HK1139153A1/xx not_active IP Right Cessation
-
2011
- 2011-02-28 HR HR20110151T patent/HRP20110151T1/hr unknown
- 2011-04-18 CY CY20111100396T patent/CY1111936T1/el unknown
-
2012
- 2012-08-21 US US13/590,227 patent/US8642619B2/en not_active Expired - Fee Related
-
2014
- 2014-01-03 US US14/147,115 patent/US9045464B2/en not_active Expired - Fee Related
-
2015
- 2015-04-15 US US14/687,051 patent/US9403773B2/en not_active Expired - Fee Related
-
2016
- 2016-06-27 US US15/193,751 patent/US20160304461A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR066872A1 (es) | Compuesto de quinolona y composicion farmaceutica | |
| PH12016501813B1 (en) | 1,3-benzodioxole derivative | |
| PE20191540A1 (es) | DERIVADOS DE PIRROLO [1,2-b] PIRIDAZINA | |
| GT200600165A (es) | Derivados dihidrobenzofuranos y usos de los mismos | |
| AR080057A1 (es) | Piridinas disustituidas como anticancerigenos | |
| DOP2012000128A (es) | Inhibidores de n1-pirazoloespirocetona acetil-coa carboxilasa | |
| GT201300179A (es) | Derivados heterociclicos novedosos y su uso en el tratamiento de trastornos neurologicos | |
| AR057915A1 (es) | Compuesto con estructura de cinamida de dos ciclos con actividad inhibitoria de la produccion de abeta40 y abeta42, un agente farmaceutico que lo comprende y el uso de este en el tratamiento de enfermedades mentales y neurodegenerativas. | |
| AR071763A1 (es) | Pirazoles trisustituidos, composiciones farmaceuticas que los contienen, y usos de los mismos en el tratamiento de trastornos neurologicos y psiquiatricos | |
| AR104714A1 (es) | Compuestos depsipeptídicos como antihelmínticos | |
| EA201391486A1 (ru) | Способы и композиции для лечения болезни паркинсона | |
| CO6331465A2 (es) | Compuesto y composición farmacéutica de quinolona | |
| CL2019001041A1 (es) | Compuestos terapéuticos y métodos para utilizarlos. | |
| EA201171305A1 (ru) | Терапевтическое средство при моторных нарушениях | |
| AR045913A1 (es) | Derivados olefinicos de 8-azabiciclo[3,2,1]octanos como antagonistas de receptores muscarinicos de acetilcolina | |
| PH12014501181A1 (en) | N- (4 -quinolinylmethyl) sulfonamide derivatives and their use as anthelmintics | |
| ECSP20066271A (es) | Derivados de pirazo-tetrahidroisoquinolina como moduladores positivos del receptor de dopamina d1 | |
| MY164789A (en) | Heterocyclic compounds for treating or preventing disorders caused by reduced neurotransmission of serotonin, norephnephrine or dopamine | |
| CO2019004547A2 (es) | Derivado de urea | |
| AR053971A1 (es) | Compuestos de (arilamidoaril) cianoguanidina, composicion farmaceutica y uso del compuesto para fabricar medicamentos | |
| PE20080279A1 (es) | DERIVADOS DE PIRAZOL[4,3-d]TIAZOL COMO INHIBIDORES DE LA PROTEINA QUINASA AURORA 1 Y 2 | |
| PL400000A1 (pl) | Nowe, podstawione pochodne dikarboksyimidów, ewentualnie w postaci farmaceutycznie dopuszczalnej soli oraz ich zastosowanie | |
| TH167999A (th) | อนุพันธ์ 1,3-เบนโซไดออกโซล | |
| TH167999B (th) | อนุพันธ์ 1,3-เบนโซไดออกโซล | |
| TH156669A (th) | สารประกอบควิโนโลน และองค์ประกอบทางเภสัชกรรม |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |